Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00287547 · ClinicalTrials.gov registry record · Phase 2
Phase II Randomized, Double-Blind, Placebo-Controlled Study of BMS-188667 (CTLA4Ig) in Patients With Psoriasis Vulgaris
A Phase 2 study of Psoriasis Vulgaris, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 2
- Development phase
- 144
- Enrollment target
- 10
- Study locations
NCT00287547: Completed Phase 2 study of Psoriasis Vulgaris, sponsored by Bristol-Myers Squibb.
NCT00287547 is a Phase 2 study of Psoriasis Vulgaris that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 144 participants, above the 68-participant average among 6 other Psoriasis Vulgaris trials with a reported enrollment target (112% higher). The trial reports 10 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00287547, a Phase 2 study of Psoriasis Vulgaris, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 144 participants
- Enrollment target
- 10
- Study locations
Study Summary
The purpose of this study is to assess the safety, pharmacokinetics and clinical activity and immunogenicity of BMS-188667 (CTLA4Ig) in subjects with psoriasis vulgaris
Conditions Studied
Interventions
- DRUG CTLA4Ig / Abatacept
Study Locations (10)
California
- Local Institution - San Diego
Illinois
- Local Institution - Chicago
Massachusetts
- Local Institution - Boston
Michigan
- Local Institution - Ann Arbor
New Jersey
- Local Institution - New Brunswick
Oregon
- Local Institution - Portland
Pennsylvania
- Local Institution - Philadelphia
Texas
- Local Institution - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 144 participants |
| Start Date | 1997-03 |
| Est. Completion | 1998-01 |
| Phase | Phase 2 |
What the finished NCT00287547 record still lists
NCT00287547 is an interventional study that assigns participants to a tested intervention. The registered 144 participants enrollment target is mid-sized for trials with a published cap, above the 68-participant average among 6 other Psoriasis Vulgaris trials with a reported enrollment target (112% higher).
The record links to 1 condition, with Psoriasis Vulgaris appearing as the primary indexed condition, and to 1 intervention - of which CTLA4Ig / Abatacept is the first listed.
NCT00287547 lists 10 locations in 10 states (California, Illinois, Massachusetts).
Frequently Asked Questions
What is clinical trial NCT00287547 about?
NCT00287547 is a clinical study titled "Phase II Randomized, Double-Blind, Placebo-Controlled Study of BMS-188667 (CTLA4Ig) in Patients With Psoriasis Vulgaris". The purpose of this study is to assess the safety, pharmacokinetics and clinical activity and immunogenicity of BMS-188667 (CTLA4Ig) in subjects with psoriasis vulgaris
What is the current status of trial NCT00287547?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 144 participants. The study started on 1997-03. Estimated completion is 1998-01.
What conditions does trial NCT00287547 study?
This clinical trial studies the following conditions: Psoriasis Vulgaris.
What interventions are being tested in trial NCT00287547?
The interventions under investigation include: CTLA4Ig / Abatacept (DRUG).
Who is sponsoring clinical trial NCT00287547?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00287547 being conducted?
This trial has 10 study locations across California, Illinois, Massachusetts, Michigan, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psoriasis Vulgaris
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety and Efficacy of TACLONEX Ointment in Adolescent Patients (Aged 12 to 17 Years) With Psoriasis Vulgaris
COMPLETED · Phase 2
-
Correction of Psoriatic T Cell Signatures by Deucravacitinib
RECRUITING · Phase 4
-
Efficacy and Safety of a Botanical Total Coumarin (TC) Cream in Treating Patients With Psoriasis Vulgaris (PLANTCOAT-III)
RECRUITING · Phase 3
-
Use of Botulinum Toxin to Treat Psoriasis
COMPLETED · Phase 1
-
Blue Light Phototherapy
COMPLETED · NA
-
A Study to Assess the Pharmacokinetics, Immunogenicity and Safety of Escalating Doses of BMS-188667 Given as a Single Intravenous Infusion to Patients With Psoriasis Vulgaris
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01861106 · 144 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations
- NCT03482245 · 144 participants · NA
The Role of Circadian Clock Proteins in Innate and Adaptive Immunity
- NCT03504683 · 144 participants · NA
MEAL TIMING Study: Effect of Time-Restricted Feeding on 24-hour Glycemic Control, Blood Pressure, and Cardiovascular Disease Risk Factors in Adults With Prediabetes
- NCT03905603 · 144 participants · Early Phase 1
Relative Contributions of Predictors of Hyperandrogenism in Older vs. Young Women With PCOS
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia